1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Oncologists Audition Yervoy And Zelboraf For First-line Roles, With New Combos In Near Sight

 
• By Emily Hayes

Cooperative group plans trial testing Yervoy vs. Zelboraf in first-line metastatic melanoma to help settle the issue of which therapy should come first in BRAF-mutation positive patients. New therapies on the way promise to further complicate decision-making.

A year ago, the arrival of two breakthrough therapies for metastatic melanoma stole the show at the American Society of Clinical Oncology annual meeting. This year, debate continued on how Bristol-Myers Squibb Co.’s immunotherapy Yervoy and Roche’s targeted Zelboraf should be used in practice: what is the best first-line option, and, especially with more agents coming, what is the potential for sequential and combination use?

Conventional thinking is that Yervoy (ipilimumab) may be the best first-line treatment for metastatic melanoma when disease is less advanced, while Roche’s targeted Zelboraf (vemurafenib) is an obvious choice for BRAF-mutation positive patients with a high tumor burden and risk of dying fast

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

US FDA Rare Disease Case Studies Provide Development Models For Sponsors

 
• By Laura Helbling

Sanofi’s Xenpozyme and Sentynyl’s Nulibry are the first two case studies the FDA is using to continue educating rare disease sponsors on best practices.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.

More from R&D

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

Unlocking Opportunities: How To Engage With The EMA On Animal Testing Alternatives

 
• By Neena Brizmohun

The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.